JackDarwin Posted - 12 hours ago

$BRKR Bullish Gap Up Formed At Downtrend. https://www.stockaio.com/US/ai/Stock/BRKR/Candlestick

Professler Posted - 1 day ago

@ScalpMaster Caught the $BRKR bounce after the CEO just purchased over 5 million in common stock.

OpenOutcrier Posted - 1 day ago

$BRKR (+4.7% pre) Form 4 BRUKER CORP For: Nov 18 Filed by: LAUKIEN FRANK H https://ooc.bz/l/48761

Estimize Posted - 1 day ago

Wall St is expecting 0.73 EPS for $BRKR Q4 [Reporting 02/18 BMO] http://www.estimize.com/intro/brkr?chart=historical&metric_name=eps&utm_co

Professler Posted - 1 day ago

$BRKR Looks like I wasn't the only one loading up at major support.

Anotherdaydate Posted - 1 day ago

$BRKR ~$5M purchase by the CEO. This may be the bottom. Worth starting a position now.

Professler Posted - 1 day ago

$BRKR How low can this go? Will we be lucky enough to buy shares under 40 soon?

Rmimidear Posted - 4 days ago

$BRKR Bruker’s innovations in life science research tools and diagnostic solutions make it a leader in healthcare technology!

swingingtech Posted - 6 days ago

$BRKR $M $PLTR https://wallstreetwaves.com/significant-thursday-options-trends-brkr-m-pltr/

Professler Posted - 1 week ago

$BRKR Back in here. I've been waiting to scoop some up in the mid 50s. As a scientist, I can vouch for their products and I absolutely love their technology. The only other mass spec MALDI that competes with them is Biomerieux and they're a French company. I would like to see Bruker manage their acquisitions and debt better in the future. This American technology company will not stay down here for long.

Jodah Posted - 1 week ago

$BRKR investrors

briefingcom Posted - 2 weeks ago

$BRKR: Bruker reports EPS in-line, revs in-line; lowers FY24 guidance https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241105070523BRKR&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

OpenOutcrier Posted - 2 weeks ago

$BRKR (-5.6% pre) Bruker Reports Third Quarter 2024 Financial Results https://ooc.bz/l/46898

Jodah Posted - 10/31/24

$BRKR tanking like a stone

Estimize Posted - 10/28/24

Wall St is expecting 866.46 revenue for $BRKR Q3 [Reporting 10/31 BMO] http://www.estimize.com/intro/brkr?chart=historical&metric_name=reve

WeeklyTrader Posted - 10/23/24

Bearish signals are flashing! $BRKR 57.5p RSI: 36.72% 50-day MA: $65.0 200-day MA: $72.64

briefingcom Posted - 1 month ago

$BRKR: Bruker announces that the European Unified Patent Court rules in favor of Bruker and NanoString ($NSTG), invalidating patent asserted by 10x genomics ($TXG) against NanoString’s CosMx SMI Products https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241017090029BRKR&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

Jodah Posted - 1 month ago

$BRKR down to the drain. Lots of debt and non-sense pricy acquisitions

WeeklyTrader Posted - 1 month ago

It's a bear party for $BRKR! RSI: 41.27% 50-day MA: $65.04 200-day MA: $72.93

themacromindset Posted - 1 month ago

$BRKR Bruker Announces Formation of New Bruker Spatial Biology Division

briefingcom Posted - 1 month ago

$BRKR: Bruker announces acquisition of Dynamic Biosensors GmbH; Financial details of the transaction were not disclosed https://www.briefing.com/in-depth-analysis/content/article?ArticleId=IN20241002070608BRKR&utm_campaign=inplay&utm_medium=social&utm_source=st&utm_content=view_page

garygb Posted - 1 month ago

$BRKR it goes up and down. Now it's going down.

Jodah Posted - 2 months ago

$BRKR

DonCorleone77 Posted - 08/28/24

$FI $DGX $CTSH $RNA $BRKR Top 5 Analyst Initiations: -- BTIG initiated coverage of Fiserv (FI) with a Buy rating and $200 price target. The firm believes the company's investment into its platforms during the past three years has positioned it to sustain high-single-digit to low-double-digit growth over the next several years. -- Evercore ISI resumed coverage of Quest Diagnostics (DGX) with an In Line rating and $165 price target. The firm sees the stock's current risk/reward profile as balanced with better fundamentals generally already reflected in the valuation. -- Jefferies reinstated coverage of Cognizant (CTSH) with a Buy rating and $90 price target after the company closed its acquisition of Belcan. The deal adds upwards of 4 percentage points of revenue on a run-rate basis and "significantly" enhances the company's capabilities in aerospace and defense, the firm tells investors. -- Wells Fargo initiated coverage of the life science tools and diagnostics group. Wells' top picks in tools are Bruker (BRKR), Repligen (RGEN) and Waters (WAT). The firm's top picks in diagnostics are Exact Sciences (EXAS) and Myriad Genetics (MYGN). Wells' Overweight rated stocks outside of its top picks are Avantor (AVTR), Maravai Lifesciences (MRVI), Agilent (A) and Thermo Fisher (TMO). The firm's Underweight rated names are Mesa Labs (MLAB) and CareDx (CDNA). -- Barclays initiated coverage of Avidity Biosciences (RNA) with an Overweight rating and $63 price target. The firm sees "meaningful market opportunity" from the company's current programs with positive read-throughs to additional muscle-targeted indications.

DonCorleone77 Posted - 08/28/24

$BRKR $RGEN $WAT $EXAS $MYGN Wells Fargo starts tools and diagnostics group with positive bias Wells Fargo last night initiated coverage of the life science tools and diagnostics group. Amid stable to improving fundamentals, Wells is positive on tools and sees select opportunities to own "attractive durable growth names at reasonable valuations," the analyst told investors in a research note. The firm says that after a two-year period of lackluster fundamentals plagued by a post-COVID reset and slowdown in China, it expects a return to more normalized mid-single-digit core revenue growth moving into the second half of 2024 and into 2025, supported by roll-off of de-stocking headwinds, improving biotech funding, instrument replacement cycle demand, emerging applied markets, rising new drug approvals, and likely contribution from China stimulus programs. Wells' top picks in tools are Bruker (BRKR), Repligen (RGEN) and Waters (WAT). In diagnostics, the analyst prefers names with diversified revenue streams across multiple large end-markets, stable-to-improving reimbursement trends and attractive pipelines that can support sustainable revenue growth. The firm's top picks in diagnostics are Exact Sciences (EXAS) and Myriad Genetics (MYGN). Wells' Overweight rated stocks outside of its top picks are Avantor (AVTR), Maravai Lifesciences (MRVI), Agilent (A) and Thermo Fisher (TMO). The firm's Underweight rated names are Mesa Labs (MLAB) and CareDx (CDNA).

insiderbuyingselling Posted - 3 months ago

$BRKR new insider selling: 4684 shares. http://insiderbuyingselling.com/?t=BRKR

mikehampel0 Posted - 3 months ago

@AllianceAdvisorsAndrea reminds me of $nstg. Declared bankruptcy, sold to a German $brkr. Shareholders got nothing. Seems this board is full of kamikaze pilots. It's too bad a large hedge fund didn't buy up before the record date and enter into a support agreement. Now I'm afraid everyone will get 0.00 instead of even 35 cents (

Stock_Titan Posted - 3 months ago

$BRKR Bruker Announces Successful Installation of 1.2 GHz Avance® NMR Spectrometer at the Korea Basic Science Institute (KBSI) https://www.stocktitan.net/news/BRKR/bruker-announces-successful-installation-of-1-2-g-hz-avance-r-nmr-8nsp8c958o6u.html

Jodah Posted - 3 months ago

$BRKR 🗑️

Stock_Titan Posted - 3 months ago

$BRKR Bruker Announces Strategic Minority Investment in NovAliX https://www.stocktitan.net/news/BRKR/bruker-announces-strategic-minority-investment-in-nov-ali-32uqvodxrnpm.html